The Photonics Play Sitting Inside Every Surgical Robot on the Market

Protect Purchasing Power (Sponsored)

Before the Next Dollar Shift, Read This

When the U.S. left the gold standard in 1971, the rules of money changed almost overnight.

Today, with inflation concerns, heavy central-bank gold buying, and questions around the dollar, some investors are taking another look at physical gold for retirement diversification.

This free guide explains the history, the risks, and how eligible retirement funds may be used for gold without triggering an immediate taxable distribution.

See How Retirement Investors Are Adding Physical Gold Before the Next Big Shift

*Reagan Gold Group does not provide financial, legal, or tax advice. This information is for educational purposes only and should not be considered investment advice. All investments carry risk, including loss of principal. Past performance is not indicative of future results. Consult your licensed financial advisor before making investment decisions.

What Just Happened

There's a small tech company you've probably never heard of, and it sells the precision motion, vision, and photonics parts inside almost every surgical robot, gene sequencer, and semiconductor inspection tool being built. After two years of choppy comps, the numbers finally turned.

Novanta (NASDAQ: NOVT) is that supplier.

Action: Start building a position around current levels ahead of the Q3 2026 earnings print expected in early November, which should confirm whether the medical robotics ramp is real. Stock is sitting just below $150 right now. Worth noting as you size the entry.

Novanta's print was the first quarter in three years where revenue growth re-accelerated across the portfolio. Medical Solutions led the way. That's the segment the market cares about most, because that's where the surgical robotics exposure lives.

Guidance stepped up after the August 5 print. Second-quarter revenue came in at $266 million, up 10% from a year earlier, with 9% of that organic. Adjusted EBITDA rose 16% to $61 million and adjusted diluted EPS climbed 17% to $0.89.

Management then guided third-quarter revenue to $300 million to $304 million, more than 21% growth, with adjusted EPS of $0.95 to $1.00. Translation for you: the OEM customers, Illumina (NASDAQ: ILMN) among them, are ordering again.

Here's the thing. Full-year revenue guidance now sits near $1.13 billion to $1.14 billion with adjusted EPS of $3.68 to $3.74, the fastest growth this business has printed in three years. The market is only starting to price that in.

What the Business Actually Does

Novanta doesn't make finished medical devices, sequencers, or lithography tools. It makes the guts inside them. The precision components other OEMs bolt into their own machines.

Think laser scanning heads, precision servo motors, machine vision optics, encoders, RFID scanners. Small parts, but a single surgical robot might contain a dozen of them, and each one gets spec'd in years before the finished product ever ships. Once you're designed in, you're basically unswappable for the life of the platform.

Customer list reads like a who's who: Intuitive, Medtronic, Stryker, J&J, Illumina, ASML, Beckman Coulter. Long product cycles, high switching costs, sticky recurring content per system.

Urgent AI warning (Sponsored)

AI & The End Of America

Some of the world’s biggest AI insiders are preparing for something most Americans are not seeing yet.

Sam Altman, Mark Zuckerberg, Peter Thiel, and other billionaires are pushing AI into the mainstream while quietly preparing for major disruption behind the scenes.

Whitney Tilson believes this could lead to a permanent reset in America, with serious financial consequences for people over 50.

He says one specific money move could help you prepare now, before the next phase of AI disruption hits.

Click here to see Whitney Tilson’s urgent AI warning and the move he says to make now.

*This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.

Why the Market Cares Again

The surgical robot pipeline is finally shipping. J&J's Ottava, Medtronic's Hugo, Stryker's Mako Spine, and a fresh wave from private players are all in late-stage rollout. Every new platform means multiple Novanta components per system, and the ramp curve for a new robot typically runs you 3 to 5 years of accelerating unit volumes.

Sequencing is refreshing too. Illumina's next-gen NovaSeq X installed base is rolling out, and the platform uses more precision motion content per instrument than the prior generation. That's a per-unit content step-up, not just a volume story.

Semi equipment is bottoming. Novanta's Photonics segment sells into lithography inspection and metrology tools. After a brutal 2024-2025 run for that end market, orders are stabilizing. Any real ASML or Applied Materials capex recovery drops right through to you.

Retirement Risk Revealed (Sponsored)

Revealed: What Washington isn’t telling you about your retirement assets

A well-known ratings firm just flagged a government retirement issue most investors haven't heard about yet.

Weiss Ratings has a track record of early warnings, including several major financial shifts over the past few decades.

Their research team put together a short briefing on what they're calling "Project Pyramid" and what it could mean for retirement accounts.

See what they found.

What the Financials Are Signaling

Gross margins are holding. Even through the demand air pocket, gross margins stayed in the high 40s. Q2 came in at 47% adjusted gross margin, up 100 basis points year over year. That's what you want to see, and it means the pricing power on custom-designed content is real.

Cash generation is intact. Operating cash flow was $64.9 million in the quarter, up from $15.1 million a year earlier, and $116.5 million year to date versus $46.8 million. That's the fuel for their bolt-on M&A engine, and Novanta has been a serial acquirer of small, complementary photonics shops.

The balance sheet has room. Gross debt was $239 million against a $719 million cash balance at quarter-end, so net leverage is actually negative, roughly $480 million of net cash. Plenty of dry powder for the next deal and no refinancing pressure hanging over the story.